No annual revenue total was found in KALARIS THERAPEUTICS, INC.'s SEC filings.
Kalaris Therapeutics, Inc. (KLRS) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$38.6 million. As of Jun 30, 2026 it held $93.5 million in cash and investments and $1.4 million in total debt.
Revenue
—
Net income
$-43.44M
+37.2% vs prior year
Operating cash flow (TTM)
$-41.02M
-27.5% vs year-ago TTM
Free cash flow
$-38.57M
+63.7% vs prior year
EPS
$-2.85
+94.5% vs prior year
Dividend per share
None
Shares outstanding
22.93M
+354.6% vs prior year
Net cash
$92.14M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- KLRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Berkeley Heights, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1754068
- Former names
- Allovir, Inc. (until Mar 12, 2025); ViraCyte, Inc. (until Oct 2, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$46.2M | -$51.7M | -$199.9M | -$171.2M | -$169.8M |
| Net income | -$43.4M | -$69.2M | -$190.4M | -$168.7M | -$172.0M |
| Diluted EPS | -$2.85 | -$51.77 | -$42.09 | -$2.20 | — |
| Operating cash flow | -$38.4M | -$20.7M | -$124.5M | -$142.1M | -$106.3M |
| Free cash flow | -$38.6M | — | — | — | -$106.3M |
| Total assets | $121.7M | $6.2M | $190.8M | $277.1M | $286.6M |
| Total liabilities | $42.9M | $56.8M | $45.0M | $52.6M | $61.3M |
| Stockholders' equity | $78.8M | -$96.6M | -$45.0M | $224.5M | $225.3M |
| Cash and investments | $118.0M | $1.6M | $183.9M | $233.8M | $248.1M |
| Total debt | $1.4M | — | $27.4M | $35.4M | $30.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 20, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 17, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 6, 2026 | Jul 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
All 699 Kalaris Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.